Neurogene : ASGCT NGN-401 Clinical Safety Poster
Preliminary Safety Results from the Ph1/2 Study of NGN-401, a Novel Regulated Gene Therapy for Rett Syndrome Suter B1, Lieberman D2, Benke T3,...
United States New York Baylor College Of Medicine Monroe Carell Jr Neurogene Inc Department Of Pediatrics
Source: marketscreener.com